Ray Therapeutics
PrivateLast Round
Series B
Apr 21, 2026
Total Funding Raised
$247M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Ray Therapeutics operates in Healthcare & Life Sciences and is based in Pleasanton, California. Its latest recorded funding round was a Series B round in April 2026.
Ray Therapeutics is a biotechnology company that develops innovative optogenetic gene therapies aimed at treating patients with blinding diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery
Business Model
B2B2C
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ray Therapeutics Comparables
Compare Ray Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gensight Biologics | 82% | |
| Bionic Sight, Inc. | 82% | |
| Beacon Therapeutics | 81% |
For institutional investors. Book with your work email.
Ray Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 21, 2026 | ||||
| Grant | Apr 24, 2025 | ||||
| Grant | Nov 13, 2023 | ||||
| Series A | May 16, 2023 | ||||
| Grant | Apr 26, 2022 | ||||
Seed | Jan 4, 2022 |
For institutional investors. Book with your work email.
Ray Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series B |
| Janus Henderson Group | Series B |
| Franklin Advisers | Series B |
| 4BIO Capital | Series A, Series B, Seed |
| Norwest Venture Partners | Series A, Series B |
| Novo Holdings | Series B |
| Adage Capital Management | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 2, 2026
Open roles increased to 42, 84% of headcount.
- Aug 21, 2026
Grew 23% QoQ, from 40 to 49 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 4, 2026
Ray Therapeutics, Inc. is developing optogenetic treatments that restore sight by making surviving retinal cells sensitive to light, although much of the research remains in the lab.
For institutional investors. Book with your work email.
Ray Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ray Therapeutics's valuation, stock price, and market status.
Is Ray Therapeutics a public or private company?
Ray Therapeutics is a private company.
What is the current stock price of Ray Therapeutics?
Ray Therapeutics is a private company, so its shares have no public market price. Caplight tracks Ray Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ray Therapeutics worth (valuation)?
Valuation information for Ray Therapeutics is not publicly available.
Can I buy Ray Therapeutics stock?
Ray Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ray Therapeutics's last funding round?
Ray Therapeutics's most recent funding round was Series B on April 21, 2026.
Who are the main investors in Ray Therapeutics?
Key investors in Ray Therapeutics include Janus Henderson Group, 4BIO Capital, California Institute for Regenerative Medicine (CIRM).
Will Ray Therapeutics IPO soon?
No public IPO plans have been announced for Ray Therapeutics.
How can I track Ray Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Ray Therapeutics's shares on secondary markets.